Revance Therapeutics reported $-62221000 in EBIT for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Ebit Change
Abbvie ABBV:US $ 5029M 601M
Aerie Pharmaceuticals AERI:US $ -33643000 85.38M
ALKERMES ALKS:US -26585000 28.97M
Bristol Myers Squibb BMY:US $ 3188M 399M
Cara Therapeutics CARA:US $ -27911000 5.61M
Coherus Biosciences CHRS:US $ -80925000 41.38M
Eli Lilly And LLY:US $ 2569.9M 171.6M
Endo International Ordinary Shares ENDP:US $ 120.25M 52.02M
Horizon Pharma HZNP:US 196.44M 99.18M
JAZZ PHA JAZZ:US 87.55M 105.43M
Johnson & Johnson JNJ:US $ 7540M 1623M
Merk MRK:US $ 5059M 207M
Neurocrine Biosciences NBIX:US $ 3.1M 60.9M
Pacira Pharmaceuticals PCRX:US $ 21.73M 24.09M
Procter & Gamble PG:US $ 4024M 1144M
Revance Therapeutics RVNC:US $ -62221000 617K
Supernus Pharmaceuticals SUPN:US $ 1.97M 26.43M
Teva Pharmaceutical Industries TEVA:US 789M 182M